S. 2512 — Enrolled Bill

One Hundred Fourteenth Congress of the United States of America 2d Session Begun and held at the City of Washington on Monday, the fourth day of January, two thousand and sixteen S. 2512 AN ACT To expand the tropical disease product priority review voucher program to encourage treatments for Zika virus. 1. Short title This Act may be cited as the Adding Zika Virus to the FDA Priority Review Voucher Program Act. 2. Expanding tropical disease product priority review voucher program to encourage treatments for Zika Virus Disease Section 524(a)(3) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360n(a)(3)) is amended— (1) by redesignating subparagraph (R) as subparagraph (S); (2) in subparagraph (Q), by striking Filoviruses and inserting Filovirus Diseases; and (3) by inserting after subparagraph (Q) the following: (R) Zika Virus Disease. . Speaker of the House of Representatives Vice President of the United States and President of the Senate